Ken Fisher's MDT Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 225,001 shares of Medtronic plc (MDT) worth $21.61 M, representing 0.01% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in MDT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2020, adding 918,007 shares. Largest reduction occurred in Q1 2025, reducing 5.16 M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Medtronic plc (MDT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Medtronic plc (MDT) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -14,528 | Reduce 6.07% | 225,001 | $96.06 |
| Q3 2025 | -34,537 | Reduce 12.60% | 239,529 | $95.24 |
| Q2 2025 | -638,446 | Reduce 69.97% | 274,066 | $87.17 |
| Q1 2025 | -5.16 M | Reduce 84.98% | 912,512 | $89.86 |
| Q4 2024 | +179,845 | Add 3.05% | 6.07 M | $79.88 |
| Q3 2024 | +609,391 | Add 11.53% | 5.89 M | $90.03 |
| Q2 2024 | +355,906 | Add 7.22% | 5.28 M | $78.71 |
| Q1 2024 | +335,964 | Add 7.32% | 4.93 M | $87.15 |
| Q4 2023 | +833,410 | Add 22.17% | 4.59 M | $82.38 |
| Q3 2023 | +496,540 | Add 15.22% | 3.76 M | $78.36 |
| Q2 2023 | -158,101 | Reduce 4.62% | 3.26 M | $88.10 |
| Q1 2023 | +117,279 | Add 3.55% | 3.42 M | $80.65 |
| Q4 2022 | +142,606 | Add 4.51% | 3.3 M | $77.72 |
| Q3 2022 | +164,915 | Add 5.50% | 3.16 M | $80.75 |
| Q2 2022 | +222,954 | Add 8.04% | 3 M | $89.75 |
| Q1 2022 | +176,360 | Add 6.79% | 2.77 M | $110.95 |
| Q4 2021 | +165,427 | Add 6.80% | 2.6 M | $103.45 |
| Q3 2021 | +147,644 | Add 6.47% | 2.43 M | $125.35 |
| Q2 2021 | +163,838 | Add 7.73% | 2.28 M | $124.13 |
| Q1 2021 | +148,876 | Add 7.55% | 2.12 M | $118.13 |
| Q4 2020 | +162,871 | Add 9.01% | 1.97 M | $117.14 |
| Q3 2020 | +231,537 | Add 14.69% | 1.81 M | $103.92 |
| Q2 2020 | +494,504 | Add 45.71% | 1.58 M | $91.70 |
| Q1 2020 | +918,007 | Add 560.47% | 1.08 M | $90.18 |
| Q4 2019 | -70,269 | Reduce 30.02% | 163,792 | $113.45 |
| Q3 2019 | +7,388 | Add 3.26% | 234,061 | $108.62 |
| Q2 2019 | -34,164 | Reduce 13.10% | 226,673 | $97.39 |
| Q1 2019 | +10,601 | Add 4.24% | 260,837 | $91.08 |
| Q4 2018 | +16,420 | Add 7.02% | 250,236 | $90.96 |
| Q3 2018 | +7,073 | Add 3.12% | 233,816 | $98.37 |
| Q2 2018 | +9,787 | Add 4.51% | 226,743 | $85.61 |
| Q1 2018 | +52,758 | Add 32.13% | 216,956 | $80.22 |
| Q4 2017 | -24,714 | Reduce 13.08% | 164,198 | $80.75 |
| Q3 2017 | +5,147 | Add 2.80% | 188,912 | $77.77 |
| Q2 2017 | +176,656 | Add 2484.96% | 183,765 | $88.75 |
| Q1 2017 | +1,013 | Add 16.62% | 7,109 | $80.60 |
| Q4 2016 | +1,147 | Add 23.18% | 6,096 | $71.19 |
| Q3 2016 | +233 | Add 4.94% | 4,949 | $86.48 |
| Q2 2016 | -302 | Reduce 6.02% | 4,716 | $88.42 |
| Q1 2016 | -887 | Reduce 15.02% | 5,018 | $77.12 |
| Q4 2015 | -34 | Reduce 0.57% | 5,905 | $76.88 |
| Q3 2015 | -506 | Reduce 7.85% | 5,939 | $67.01 |
| Q2 2015 | -272 | Reduce 4.05% | 6,445 | $74.17 |
| Q1 2015 | +6,717 | New Buy | 6,717 | $78.01 |
Ken Fisher's Medtronic plc Investment FAQs
Ken Fisher first purchased Medtronic plc (MDT) in Q1 2015, acquiring 6,717 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Medtronic plc (MDT) for 44 quarters since Q1 2015.
Ken Fisher's largest addition to Medtronic plc (MDT) was in Q1 2020, adding 1,081,799 shares worth $97.56 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 225,001 shares of Medtronic plc (MDT), valued at approximately $21.61 M.
As of the Q4 2025 filing, Medtronic plc (MDT) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Medtronic plc (MDT) was 6,073,565 shares, as reported at the end of Q4 2024.